Why is Pfizer falling/rising?

As of 24-Jul, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,255.00, which reflects a decrease of 35.05 points or 0.66%. The stock has underperformed its sector today by 1.01%, and its delivery volume has fallen significantly by 25.09% compared to the 5-day average, indicating reduced investor participation. Over the past week, the stock has decreased by 2.14%, and over the last month, it has seen a decline of 5.46%. Despite these short-term challenges, the company maintains a high management efficiency with a return on equity (ROE) of 19.67% and a low debt-to-equity ratio, which could provide some stability in the long run.
In the broader market context, the Sensex has shown a slight decline of 0.09% over the past week, contrasting with Pfizer's more significant drop. While the stock has a year-to-date return of just 0.02%, the benchmark has risen by 5.18% during the same period, highlighting the stock's underperformance relative to the market. Additionally, despite the current price decline, Pfizer's high dividend yield of 3.78% may attract some investors looking for income, but the overall negative momentum and falling investor participation suggest that the stock is facing challenges that could hinder its recovery in the short term.